For decades, people with obesity were told the solution was simple: eat less, move more, try harder. When that didn’t work, they were blamed. But science has always told a different story: obesity is a chronic, biologically driven disease, just like diabetes or hypertension. And right now, we’re witnessing the most significant transformation in obesity medicine that has ever happened.

The new GLP-1 medications like Wegovy and Zepbound are making headlines everywhere, but with breakthrough treatments come big questions. Who should take them? How do you know which one is right for you? What happens when you stop? And with millions of people getting these medications online or from providers with little expertise, how do you ensure you’re getting safe, effective care?

Join Holly and Jim as they sit down with Dr. Louis Aronne, one of the true pioneers who shaped this revolution from the very beginning. For over 30 years, Dr. Aronne has been on the front lines, treating patients and conducting research at one of the premier obesity centers in the country. He’ll share the real story behind these medications, what he’s learned from treating 9,000 patients, and where obesity treatment is heading next.

Discussed on the episode:

The mouse experiment from the 1980s that changed everything about how we understand weight
Why some people feel amazing on Wegovy while others do better on Zepbound
The creative dosing strategies that help patients who can’t tolerate standard doses
What happens to the majority of people who stop taking GLP-1 medications
The surprising parallel between treating obesity and treating high blood pressure
Why registered dietitians could be the perfect providers for obesity care
The 15 new medications coming in the next five years that will transform access
How these medications prevent 94% of diabetes cases in people with prediabetes
The simple eating strategy that works almost like taking medicine
What it really means when people say taking medication is cheating